Todd Bridges, RPh
Drug Safety Institute (DSI) is a wholly-owned subsidiary of Brand Institute. DSI provides a portfolio of industry-leading guidance pertaining to drug name safety (i.e., preventing medication errors), packaging, and labeling.
In 1999, the FDA formed the Division of Medication Errors and Technical Support (DMETS), signaling that the agency was laser-focused on reducing naming-related medication errors. At that time, Brand Institute started developing a name safety research methodology that would be fully compliant with the agency’s guidance and expectations. In 2003, we formed Drug Safety Institute and recruited Jerry Phillips, former Acting Director of FDA’s DMETS, to lead our new subsidiary. We have since staffed DSI with a “who’s who” of regulatory experts from the Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada (HC), American Medical Association (AMA), and the World Health Organization (WHO). These experts provide our clients with industry-leading guidance pertaining to drug name safety (i.e., preventing medication errors), packaging, and labeling. Today, we proudly partner on over 75% of approved pharmaceutical brand and nonproprietary names worldwide annually.
To provide the global pharmaceutical and biotech communities with regulatory expertise, strategy, and best practices in brand name and nonproprietary (USAN/INN) name development, name safety research, and comprehensive regulatory solutions.
President, U.S. Regulatory Affairs
President, EU Regulatory Affairs
President, Canadian Regulatory Affairs
Senior Vice President, Regulatory Affairs ‑ Nonproprietary
Senior Vice President, Regulatory Affairs, Nonproprietary Names Division
Vice President, EU Regulatory Affairs & Safety Research